Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + envafolimab for metastatic uveal melanoma
ChiCTR2400085194Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat and envafolimab in intraocular melanoma, sponsored by Shanghai Ninth People's Hospital. Started Jun 2024; status: recruiting.
02
Drugs
tucidinostatenvafolimab
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on ChiCTR2400085194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085194.